NCT06582628 - Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2027

Conditions

Metastatic Prostate Cancer

Interventions

DRUG

Enzalutamide capsule

Enzalutamide capsules 160 mg orally daily

DRUG

Enzalutamide capsule and Talazoparib capsule

Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily

Trial Locations (12)

11407

RECRUITING

Hospital Universitario de Jerez de la Frontera, Cadiz

28040

RECRUITING

Hospital Clínico San Carlos, Madrid

28041

RECRUITING

Hospital 12 de Octubre, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

29010

RECRUITING

Hospital Universitario Virgen de la Victoria, Málaga

39008

RECRUITING

Hospital Universitario Marqués de Valdecilla, Santander

48903

RECRUITING

Hospital Universitario Cruces, Barakaldo

08916

RECRUITING

Institut Català d'Oncologia (ICO), Badalona

08208

RECRUITING

Consorcio Corporación Sanitaria Parc Taulí, Sabadell

08003

RECRUITING

Hospital Universitario Del Mar., Barcelona

08036

RECRUITING

Hospital Clínico y Provincial de Barcelona, Barcelona

50009,

RECRUITING

Hospital Universitario Miguel Servet, Zaragoza